These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18174595)

  • 1. Doctor takes "march of shame" to atone for drug company payments.
    Lenzer J; Brownlee S
    BMJ; 2008 Jan; 336(7634):20-1. PubMed ID: 18174595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug company payments: Speakers should declare funding.
    Taylor MS
    BMJ; 2008 Feb; 336(7638):234. PubMed ID: 18244973
    [No Abstract]   [Full Text] [Related]  

  • 3. Australian regulator insists on greater transparency of industry payments to doctors.
    Coopes A
    BMJ; 2014 Oct; 349():g6335. PubMed ID: 25331811
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug company payments: Put declaration in abstracts.
    Stanton R
    BMJ; 2008 Feb; 336(7640):345. PubMed ID: 18276678
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharma PR or medical education?
    Rentmeester CA
    Hastings Cent Rep; 2005; 35(2):6. PubMed ID: 15957306
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug companies will have to report all payments to US doctors from March 2014.
    Roehr B
    BMJ; 2013 Feb; 346():f826. PubMed ID: 23393117
    [No Abstract]   [Full Text] [Related]  

  • 7. Money for drugs: should physicians be paid for pharmaceutical development and clinical investigations?
    Van Way C; Bohigian G; Gale A; Powell M; Hagan JC
    Mo Med; 2011; 108(5):320-9. PubMed ID: 22073488
    [No Abstract]   [Full Text] [Related]  

  • 8. Conflicts of interest: part 1: Reconnecting the dots--reinterpreting industry-physician relations.
    Rosenbaum L
    N Engl J Med; 2015 May; 372(19):1860-4. PubMed ID: 25946288
    [No Abstract]   [Full Text] [Related]  

  • 9. Conflicts of Interest.
    Strandberg TE
    N Engl J Med; 2015 Aug; 373(8):779. PubMed ID: 26287865
    [No Abstract]   [Full Text] [Related]  

  • 10. Conflicts of Interest.
    Fleischman W; Newman DH
    N Engl J Med; 2015 Aug; 373(8):778-9. PubMed ID: 26287864
    [No Abstract]   [Full Text] [Related]  

  • 11. Conflicts of Interest.
    Roper N
    N Engl J Med; 2015 Aug; 373(8):778. PubMed ID: 26287863
    [No Abstract]   [Full Text] [Related]  

  • 12. Conflicts of Interest.
    Abramson J; Redberg R
    N Engl J Med; 2015 Aug; 373(8):778. PubMed ID: 26287862
    [No Abstract]   [Full Text] [Related]  

  • 13. Conflicts of Interest.
    Rosenbaum L
    N Engl J Med; 2015 Aug; 373(8):779-80. PubMed ID: 26287861
    [No Abstract]   [Full Text] [Related]  

  • 14. No more free lunches: it is time we all grew up.
    Wessely S
    BMJ; 2003 Aug; 327(7410):341. PubMed ID: 12907497
    [No Abstract]   [Full Text] [Related]  

  • 15. US Senate committee investigates conflicts of interest in industry funded medical education.
    Tanne JH
    BMJ; 2009 Aug; 339():b3139. PubMed ID: 19654162
    [No Abstract]   [Full Text] [Related]  

  • 16. Matters arising from industry link to education.
    Mathew JL
    BMJ; 2008 Sep; 337():a1781. PubMed ID: 18812381
    [No Abstract]   [Full Text] [Related]  

  • 17. Distributions of industry payments to Massachusetts physicians.
    Kesselheim AS; Robertson CT; Siri K; Batra P; Franklin JM
    N Engl J Med; 2013 May; 368(22):2049-52. PubMed ID: 23635021
    [No Abstract]   [Full Text] [Related]  

  • 18. End of the free lunch?
    Gould M
    BMJ; 2008 Aug; 337():a1399. PubMed ID: 18728077
    [No Abstract]   [Full Text] [Related]  

  • 19. Truly independent research?
    Lenzer J
    BMJ; 2008 Aug; 337():a1332. PubMed ID: 18719008
    [No Abstract]   [Full Text] [Related]  

  • 20. Individual drug firms should stop paying for medical education.
    Kmietowicz Z
    BMJ; 2009 Feb; 338():b442. PubMed ID: 19193684
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.